FILE - Employees pack boxes containing vials of Covishield, a version of the AstraZeneca vaccine, at the Serum Institute of India in Pune on Monday, Nov. 22, 2021. The Serum Institute of India, the world’s largest vaccine maker, has manufactured millions of Novavax doses, but none went to COVAX. According to India’s Ministry of External Affairs and the institute, more than 28.9 million Novavax doses were sent to the Netherlands in January and February, while Australia received about 6 million doses. Indonesia also received about 9 million doses in December. (AP Photo/Rafiq Maqbool, File)
FILE - Kidney dishes with mounted syringes containing vaccines, from top, Novavax, Biontech and Moderna sit in a refrigerator in a vaccination center ready for vaccination in Prisdorf, Germany, Saturday, Feb. 26, 2022. Even with vaccine supplies improving, some officials were eagerly awaiting the Novavax vaccine in particular because it is easier to transport and store than some other coronavirus shots. (Georg Wendt/dpa via AP, File)
FILE - A worker moves boxes carrying Novavax's COVID-19 vaccine at SK Bioscience Co. in Andong, South Korea, on Feb. 9, 2022. Before the pandemic, Novavax was a small American company that had never brought any vaccine to market. Its shots have proven highly effective, but it is relying heavily on other companies to make them. (Kim Hyun-tae/Yonhap via AP, File)
NEW DELHI — The company behind a COVID-19 vaccine touted as a key tool for the developing world has sent tens of millions of doses to wealthy nations but provided none yet to the U.N.-backed effort to supply poorer countries, a sign that inequity persists in the global response to the pandemic.